- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06386198
HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients (HEAL-Tx:ToC)
April 23, 2024 updated by: University of California, San Francisco
The Health Advocate for Liver Transplant (HEAL-Tx) Transition of Care Pilot is a nonrandomized, open-label intervention pilot of a health advocate intervention aimed to assess feasibility and acceptability of integrating a Health Advocate onto the transplant team to help adolescents transition their care to adult transplant teams.
Across studies, health advocate roles vary, and can include coordinating medical care treatment, facilitating financial assistance (e.g., taxi vouchers), and connecting patients to community resources, which can improve self-management, mitigate social risks, and lead to better communication between the healthcare system and the family.
In this pilot, the investigators will adapt this intervention for adolescent/young adult liver transplant patients and measure acceptability and feasibility according to RE-AIM.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sharad Wadhwani, MD, MPH
- Phone Number: 510-428-3058
- Email: sharad.wadhwani@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- University of California San Francisco
-
Contact:
- Emily Stekol
- Phone Number: 415-502-3190
- Email: emily.stekol@ucsf.edu
-
Principal Investigator:
- Sharad Wadhwani, MD, MPH
-
-
Georgia
-
Atlanta, Georgia, United States, 30345
- Not yet recruiting
- Children's Healthcare of Atlanta
-
Principal Investigator:
- Nitika Gupta
-
Contact:
- Nitika Gupta
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient has received a liver transplant >1 year ago
- Study team has screened patient and discussed with the primary transplant practitioner that patient may benefit from the Health Advocate program.
- Patient has an unmet social risk (e.g., food insecurity) or MLVI >/= 2.0.
- Patient will be transferred to adult transplant team in <6 months.
- Patient can read and write English or Spanish
- Patient is between 18-25 years old and can provide informed consent.
- Patient has a working phone and smart device capable of video and/or audio virtual visits via Zoom.
Exclusion Criteria:
- Patient has significant cognitive impairment.
- Does not meet age criteria
- Patient is a ward of the state.
- Non-English, non-Spanish speakers.
- Non-US residents.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
This is a single arm pilot intervention.
|
The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in patient experience
Time Frame: Baseline and 180 days
|
The investigators will administer a survey of patient experience at study enrollment and at the end of the intervention to assess for changes in patient experience with the transplant team.
These questions will focus on experiences receiving transplant care, experiences discussing social needs with the transplant team, and overall subjective assessment of the transplant recipient's overall health.
|
Baseline and 180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in medication adherence using MLVI
Time Frame: Baseline and 180 days
|
Medication level variability index (MLVI) defined as the standard deviation of at least 3 outpatient tacrolimus trough levels (binary >/=2.0 or <2.0).
The investigators will assess this at study entry and again at 180 days.
|
Baseline and 180 days
|
The quality of health advocate interactions with the participants, healthcare team, and community-based resources.
Time Frame: 180 days
|
The Health Advocate will keep a detailed journal entry after each encounter and certain Health Advocate interactions will be recorded.
The investigators will qualitatively analyze these journal entries and recordings to identify what functions the health advocate undertook.
|
180 days
|
A qualitative assessment of patient and healthcare provider satisfaction with the Health Advocate intervention.
Time Frame: 180 days
|
The investigators will conduct in-depth interviews with the patient participant and clinical team members to assess overall satisfaction with the intervention.
|
180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sharad Wadhwani, MD, MPH, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2024
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
April 23, 2024
First Submitted That Met QC Criteria
April 23, 2024
First Posted (Actual)
April 26, 2024
Study Record Updates
Last Update Posted (Actual)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 23-40699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric ALL
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
University Hospital, Strasbourg, FranceTerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung DiagnosisFrance
-
TC Erciyes UniversityCompletedPediatric Cancer | Pediatric Brain Tumor | Pediatric Solid TumorTurkey
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital; Stollery... and other collaboratorsNot yet recruitingPediatric Cancer | Pediatric Hematology
-
Children's Healthcare of AtlantaEmory UniversityCompletedPediatric Preoperative Anxiety, Pediatric CopingUnited States
-
Hospital Moinhos de VentoNot yet recruitingAdolescent | Telemedicine | Critical Care | Pediatric | Intensive Care Units, Pediatric
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
Clinical Trials on Health Advocate
-
Massachusetts General HospitalAvera McKennan Hospital & University Health Center; South Dakota State UniversityRecruiting
-
University of California, San FranciscoKaiser Permanente; Nina Ireland Program in Lung HealthCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingPediatric ALL | Liver Transplant; ComplicationsUnited States
-
Boston Medical CenterNortheastern UniversityCompletedPreconception CareUnited States
-
Boston Children's HospitalCompletedChildren's Diet Quality | Health-related Social ProblemsUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of PennsylvaniaCompletedAsthma | CommunicationUnited States
-
Boston Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD); Northeastern...CompletedPreconception CareUnited States
-
RTI InternationalNew Jersey Prevention Network; RWJBarnabas Health Institute for Prevention...RecruitingSubstance-Related Disorders | Adverse Childhood ExperiencesUnited States
-
University of Maryland, BaltimoreCompleted